Drug intelligence / Profile preview

sericin

Development stage
Unknown
Lead developer
Chulalongkorn University
Modality
Recombinant Proteins and Enzymes
Administration
Topical, Injectable, Surgical Implantation
01

Overview

Sericin is a **silkworm-derived protein mixture** obtained from *Bombyx mori* cocoons and developed as a topical biologically active material rather than as a conventional single-molecule drug. Across the provided sources, sericin is described as having **anti-inflammatory and wound-healing activity**, including suppression of pro-inflammatory cytokines such as TNF-alpha, IL-6, IL-12p40, and IL-23 in ex vivo human peripheral blood mononuclear cells from patients with psoriasis, and promotion of corneal epithelial repair in ocular injury and diabetic keratopathy models. Clinical development in the provided records is mainly in **topical cream formulations** combined with chitosan for pressure sores and with turmeric for psoriasis, while publications also describe ophthalmic use as an additive to benzalkonium chloride-containing timolol eye drops. Sericin should be treated here as the specific active ingredient itself, not as the naringin + sericin combination product.

Other names
silkworm sericinBombyx mori sericinsilk sericin
02

Targets

NF-κBMYD88 (Myeloid differentiation primary response protein MyD88)

Beyond the preview

Go deeper on sericin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on sericin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call